Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
18.6M
-
Shares change
-
-233K
-
Total reported value, excl. options
-
$216M
-
Value change
-
-$2.77M
-
Put/Call ratio
-
2.54
-
Number of buys
-
40
-
Number of sells
-
-41
-
Price
-
$11.65
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q2 2021
104 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q2 2021.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.6M shares
of 43.4M outstanding shares and own 42.8% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.68M shares), BlackRock Inc. (2.15M shares), VANGUARD GROUP INC (1.56M shares), Corriente Advisors, LLC (1.49M shares), Slate Path Capital LP (1.48M shares), STATE STREET CORP (1.47M shares), 683 Capital Management, LLC (704K shares), Woodline Partners LP (667K shares), Prosight Management, LP (630K shares), and GEODE CAPITAL MANAGEMENT, LLC (516K shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.